Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
13
|
pubmed:dateCreated |
1998-8-28
|
pubmed:abstractText |
Children of constitutionally tall stature may experience serious problems related to their height. Treatment with high dose sex steroids may be considered in order to limit final adult height. Prediction of adult height plays a central part in the management of children of tall stature. Various aspects of height prediction in children of tall stature are discussed. The height reducing effect varies between studies from 2 to 10 cm. Recently, in a large Dutch study the mean effects of therapy were 0.7 and 2.4 cm for boys and girls respectively. The effect depended on the bone age at start of treatment. Beyond a critical bone age of about 14 years treatment had no effect. Minimal age for intervention is 9.5-10 year for boys and 9.0-9.5 year for girls. Recommended treatment for boys is 250 mg testosterone esters i.m. per week and for girls ethinyloestradiol orally 200 micrograms per day in combination with medroxyprogesterone or dydrogesterone (both 5-10 mg per day) during the first 12-14 days of the cycle. Treatment has to be continued until complete closure of the epiphyses. While side effects during hormonal therapy are frequent, they are mostly temporary and mild and seldom lead to cessation of therapy. So far there have been no indications of adverse effects on, for instance, gonadal function.
|
pubmed:commentsCorrections | |
pubmed:language |
dut
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Dydrogesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Ethinyl Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Medroxyprogesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Progesterone Congeners,
http://linkedlifedata.com/resource/pubmed/chemical/Testosterone
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0028-2162
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
28
|
pubmed:volume |
142
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
693-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9623141-Administration, Oral,
pubmed-meshheading:9623141-Adolescent,
pubmed-meshheading:9623141-Body Height,
pubmed-meshheading:9623141-Child,
pubmed-meshheading:9623141-Drug Therapy, Combination,
pubmed-meshheading:9623141-Dydrogesterone,
pubmed-meshheading:9623141-Ethinyl Estradiol,
pubmed-meshheading:9623141-Female,
pubmed-meshheading:9623141-Growth Disorders,
pubmed-meshheading:9623141-Humans,
pubmed-meshheading:9623141-Injections, Intramuscular,
pubmed-meshheading:9623141-Male,
pubmed-meshheading:9623141-Medroxyprogesterone,
pubmed-meshheading:9623141-Progesterone Congeners,
pubmed-meshheading:9623141-Testosterone
|
pubmed:year |
1998
|
pubmed:articleTitle |
[Hormonal therapy of constitutionally tall children].
|
pubmed:affiliation |
Academisch Ziekenhuis Rotterdam-Sophia Kinderziekenhuis, subafd. Endocrinologie.
|
pubmed:publicationType |
Journal Article,
English Abstract,
Review,
Research Support, Non-U.S. Gov't
|